What are the possible complications of parathyroid hormone (PTH) for the treatment of osteoporosis?

Updated: Jan 20, 2021
  • Author: Rachel Elizabeth Whitaker Elam, MD, MSc; Chief Editor: Herbert S Diamond, MD  more...
  • Print

When PTH is given continuously, both osteoclastic and osteoblastic turnover increase, leading to a net loss of bone. However, intermittent subcutaneous administration of PTH in a dosage of 20 mcg/day has been demonstrated to induce a very active anabolic phase, with bone mass increasing up to 13% over 2 years in the spine and to a lesser degree in the hip. [174, 175, 176]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!